Eli Lilly bulks up in Ireland

In anticipation of increased demand for biopharmaceuticals, Eli Lilly ($LLY) is planning a 22,000-square-meter bioprocessing plant at its Cork County site. The Dunderrow, Kinsale, location is currently home to API production for drugs to treat diabetes, schizophrenia and depression, according to the Irish Times. Lilly's presence in Dunderrow stretches back to the early 1980s, InPharm notes.

Plans call for a three-story building on the site, in proximity to a 158,000-square-meter monoclonal antibody plant completed in 2010 and expected to be online next year. The site, one of 6 Lilly bulk manufacturing locations worldwide, is the production home for potential blockbuster Alzheimer treatment solanezumab, InPharm reports.

Eli Lilly isn't the only big drugmaker expanding its presence in Ireland. In October, Sanofi ($SNY) unit Genzyme unveiled a $207 million plant expansion in Waterford, about 150 kilometers east of the Lilly site along the coast in the south of the Emerald Isle.

- here's the story
- see the InPharm report

Special Report: Eli Lilly - The 12 greenest companies in biopharma

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.